Elahere, validated in a phase 3 trial, is FDA-approved and offers the first major advancement for platinum-resistant ovarian cancer in decades.
Dr. Ryan Kahn
Advertisement
Articles by Dr. Ryan Kahn
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
Every FDA Oncology Approval From November 2025
2
What Patients With AML Need to Know About Azacitidine and Venclexta
3
FDA Approves Breyanzi in Relapsed/Refractory Marginal Zone Lymphoma
4
How Therapeutic Vaccines May Transform Lung Cancer Care
5
